News Archive | Theragnostics

Take a trip down Theragnostics memory lane with our news archive below

Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScan^TM (Kit for the Preparation of Technetium Tc 99m Succimer Injection)

February 22, 2022

Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK’s MHRA Innovation Passport

February 10, 2022

Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET Radiopharmaceuticals

September 22, 2021

Theragnostics Strengthens Board of Directors with Key Appointments

August 4, 2021

Theragnostics Announces a research collaboration with Essen University Hospital to study THG-008 for Oncology PET Imaging

February 17, 2021

Developing radionuclide PARP inhibitors – MedNous Article

November 19, 2020

Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare Conference

November 10, 2020

Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer Diagnostics

September 9, 2020

Theragnostics CEO Greg Mullen presenting at Targeted Radiopharmaceuticals Summit

June 12, 2019

Is it June already?! – Meet us @ SNMMI ’19

June 6, 2019

Theragnostics Expands Team with Significant Appointments

January 10, 2020

Theragnostics strengthens leadership team with two key appointments

November 13, 2019

GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancer

October 9, 2019

Theragnostics Reports Positive Clinical Trial
Results from Prostate Cancer Study

October 2, 2019

Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScan^TM (Kit for the Preparation of Technetium Tc 99m Succimer Injection)

February 22, 2022

Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK’s MHRA Innovation Passport

February 10, 2022

Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET Radiopharmaceuticals

September 22, 2021

Theragnostics Strengthens Board of Directors with Key Appointments

August 4, 2021

Theragnostics Announces a research collaboration with Essen University Hospital to study THG-008 for Oncology PET Imaging

February 17, 2021

Developing radionuclide PARP inhibitors – MedNous Article

November 19, 2020

Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare Conference

November 10, 2020

Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer Diagnostics

September 9, 2020

Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScan^TM (Kit for the Preparation of Technetium Tc 99m Succimer Injection)

February 22, 2022

Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK’s MHRA Innovation Passport

February 10, 2022

Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET Radiopharmaceuticals

September 22, 2021

Theragnostics Strengthens Board of Directors with Key Appointments

August 4, 2021

Theragnostics Announces a research collaboration with Essen University Hospital to study THG-008 for Oncology PET Imaging

February 17, 2021

Developing radionuclide PARP inhibitors – MedNous Article

November 19, 2020

Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare Conference

November 10, 2020

Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer Diagnostics

September 9, 2020

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
JSESSIONID	session	The JSESSIONID cookie is used by New Relic to store a session identifier so that New Relic can monitor session counts for an application.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
bcookie	2 years	LinkedIn sets this cookie from LinkedIn share buttons and ad tags to recognize browser ID.
bscookie	2 years	LinkedIn sets this cookie to store performed actions on the website.
lang	session	LinkedIn sets this cookie to remember a user's language setting.
lidc	1 day	LinkedIn sets the lidc cookie to facilitate data center selection.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_ZNEJ7GCH20	2 years	This cookie is installed by Google Analytics.

Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScanTM (Kit for the Preparation of Technetium Tc 99m Succimer Injection)

Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK’s MHRA Innovation Passport

Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET Radiopharmaceuticals

Theragnostics Strengthens Board of Directors with Key Appointments

Theragnostics Announces a research collaboration with Essen University Hospital to study THG-008 for Oncology PET Imaging

Developing radionuclide PARP inhibitors – MedNous Article

Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare Conference

Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer Diagnostics

Theragnostics Collaborate on £6 million MITHRAS Research Programme

Dr Greg Mullen, Theragnostics CEO Gains Leadership Recognition

Theragnostics attending PSMA Masterclass – London

Theragnostics attending JPM in San Francisco

Theragnostics will be @ EANM ’19 – Booth #4

THERAGNOSTICS SIGNS AGREEMENT WITH ASTRAZENECA

Theragnostics CEO Greg Mullen presenting at Targeted Radiopharmaceuticals Summit

Is it June already?! – Meet us @ SNMMI ’19

Theragnostics Expands Team with Significant Appointments

Theragnostics strengthens leadership team with two key appointments

GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancer

Theragnostics Reports Positive Clinical Trial Results from Prostate Cancer Study

Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScanTM (Kit for the Preparation of Technetium Tc 99m Succimer Injection)

Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK’s MHRA Innovation Passport

Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET Radiopharmaceuticals

Theragnostics Strengthens Board of Directors with Key Appointments

Theragnostics Announces a research collaboration with Essen University Hospital to study THG-008 for Oncology PET Imaging

Developing radionuclide PARP inhibitors – MedNous Article

Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare Conference

Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer Diagnostics

Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScanTM (Kit for the Preparation of Technetium Tc 99m Succimer Injection)

Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK’s MHRA Innovation Passport

Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET Radiopharmaceuticals

Theragnostics Strengthens Board of Directors with Key Appointments

Theragnostics Announces a research collaboration with Essen University Hospital to study THG-008 for Oncology PET Imaging

Developing radionuclide PARP inhibitors – MedNous Article

Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare Conference

Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer Diagnostics

Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScan^TM (Kit for the Preparation of Technetium Tc 99m Succimer Injection)

THERAGNOSTICS SIGNS AGREEMENT
WITH ASTRAZENECA

Theragnostics Reports Positive Clinical Trial
Results from Prostate Cancer Study

Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScan^TM (Kit for the Preparation of Technetium Tc 99m Succimer Injection)

Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScan^TM (Kit for the Preparation of Technetium Tc 99m Succimer Injection)